Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azilsartan for OSAS-related hypertension with coronary artery disease
ChiCTR2400090302Phase 4Not yet recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of azilsartan in hypertension (HTN), coronary arteriosclerosis and obstructive sleep apnea hypopnea syndrome (OSAHS) (2 arms), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoints: Blood pressure at month 12, Symptoms of angina at month 12 and 3 more. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
azilsartan
03
Conditions
hypertension (HTN)coronary arteriosclerosisobstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on ChiCTR2400090302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090302.